Skip to content
DataLookout
Menu

NCT05468489

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 27 versions: 26 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Phase changed: Phase 3 → Phase 2
    • Eligibility criteria expanded, about 716 words
    • Study sites: 67 to 65
    • Secondary endpoints: 6 to 10
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 99 to 67
    • Primary completion date: Sep 30, 2025 to Feb 28, 2026
    • Study completion date: Dec 31, 2025 to Dec 31, 2027
    v26
  3. Minor Site details revised at 6 of 99 sitesv25
  4. Minor Primary completion date: Apr 30, 2025 to Sep 30, 2025
    • Study sites revised (99)
    v24
  5. Notable Primary completion date: Oct 31, 2024 to Apr 30, 2025
    • Site details revised at 5 of 99 sites
    v23
Show 20 earlier versionsHide 20 earlier versions
  1. Minor Study sites: 87 to 99v22
  2. Minor Study sites revised (87)v21
  3. Minor Study sites: 84 to 87v20
  4. Notable Phase: Phase 2 to Phase 3v19
  5. Notable Phase: Phase 3 to Phase 2v18
  6. Minor Primary completion date: Jun 1, 2024 to Oct 31, 2024v17
  7. Minor Study sites: 83 to 84v16
  8. Minor Study sites: 79 to 83v15
  9. Minor Study sites: 69 to 79v14
  10. Minor Study sites: 64 to 69v13
  11. Minor Study sites: 57 to 64v12
  12. Notable Eligibility criteria expanded, about 108 wordsv11
  13. Minor Study sites: 38 to 57v10
  14. Minor Study sites: 15 to 38v9
  15. Minor Interventions: Atezolizumab + chemotherapy (carboplatin-etoposide) (Drug), HLX10 + chemotherapy (carboplatin-etoposide) (Drug) to Atezolizumab + chemotherapy (carboplatin-etoposide) (Drug), Serplulimab + chemotherapy (carboplatin-etoposide) (Drug)
    • Secondary endpoints: details revised at 3 of 6 entries
    • Study title revised
    v8
  16. Minor Study sites: 11 to 15v6
  17. Minor Study sites: 5 to 11
    • Start date changed from estimate of Oct 12, 2022 to Nov 18, 2022
    v5
  18. Minor Study sites: 1 to 5v4
  19. Minor Start date: Oct 20, 2022 to Oct 12, 2022v3
  20. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Sep 1, 2022 to Oct 20, 2022
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

OS
Timeframe: A period from randomization through death regardless of causality (approximately up to 24 months).

Secondary (10)

Objective response rate (ORR)
Progression-free survival (PFS)
PFS2
Duration of response (DOR)
Adverse events
Show 5 moreShow less
Observed concentration of HLX10 in serum
Estimated PK exposure of HLX10 in serum from population pharmacokinetic analysis, expressed as mg·h/L
HLX10 anti-drug antibody (ADA)
Neutralizing antibody (NAb)
Quality of life assessment

Arms and interventions

Serplulimab + chemotherapyExperimental

Serplulimab + chemotherapy (carboplatin-etoposide)

Atezolizumab + chemotherapyActive comparator

Atezolizumab + chemotherapy (carboplatin-etoposide)

Drugs: Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide)

Sites

65 sites in 1 country